Trial · NCT01095497
Results by group165
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 165
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Intravenous (IV) CINRYZE | Number of subjects with adverse events | 12 | 0.019 | Participants |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Subcutaneous (SC) CINRYZE Dose 1 | Number of subjects with adverse events | 10 | 0.027 | Participants |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | SC CINRYZE Dose 2 | Number of subjects with adverse events | 11 | 0.010 | Participants |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Intravenous (IV) CINRYZE | Number of subjects with injection site reactions | 1 | 0.033 | Participants |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Subcutaneous (SC) CINRYZE Dose 1 | Number of subjects with injection site reactions | 10 | 0.032 | Participants |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | SC CINRYZE Dose 2 | Number of subjects with injection site reactions | 11 | 0.010 | Participants |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Intravenous (IV) CINRYZE | Number of subjects who discontinued study drug | 1 | Participants | |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Subcutaneous (SC) CINRYZE Dose 1 | Number of subjects who discontinued study drug | 0 | Participants | |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | SC CINRYZE Dose 2 | Number of subjects who discontinued study drug | 0 | Participants | |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Intravenous (IV) CINRYZE | Number of subjects who withdrew from the study | 1 | Participants | |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | Subcutaneous (SC) CINRYZE Dose 1 | Number of subjects who withdrew from the study | 1 | Participants | |
| Incidence and Severity of Adverse Events, Number of Subjects With Local Injection Site Reactions, and Number of Subjects Who Discontinue Study Drug or Withdraw From the Study. | SC CINRYZE Dose 2 | Number of subjects who withdrew from the study | 0 | Participants | |
| Mean Change C1 Inhibitor (C1INH) | Intravenous (IV) CINRYZE | 1 hour (h) post Dose 1 | 0.075 | Standard Deviation 0.023 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) CYNRYZE Dose 1 | 1 hour (h) post Dose 1 | -0.002 | Standard Deviation 0.008 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC Dose 2 | 1 hour (h) post Dose 1 | -0.001 | Standard Deviation 0.006 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Intravenous (IV) CINRYZE | 2 h post Dose 1 | 0.070 | Standard Deviation 0.021 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) CYNRYZE Dose 1 | 2 h post Dose 1 | -0.002 | Standard Deviation 0.008 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC Dose 2 | 2 h post Dose 1 | -0.001 | Standard Deviation 0.004 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Intravenous (IV) CINRYZE | 3 h post Dose 1 | 0.070 | Standard Deviation 0.023 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) CYNRYZE Dose 1 | 3 h post Dose 1 | -0.002 | Standard Deviation 0.007 | g/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01095497/results